{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Elimusertib", "query": { "intervention": "Elimusertib" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-02T21:49:56.905Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03188965", "title": "First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non-Hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Elimusertib (BAY1895344)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2017-07-06", "completion_date": "2023-09-13", "has_results": false, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 14, "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia + 10 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03188965" }, { "nct_id": "NCT04576091", "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Recurrent Head and Neck Cutaneous Squamous Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Hypopharyngeal Squamous Cell Carcinoma", "Recurrent Laryngeal Squamous Cell Carcinoma", "Recurrent Oral Cavity Squamous Cell Carcinoma", "Recurrent Oropharyngeal Squamous Cell Carcinoma", "Recurrent Paranasal Sinus Squamous Cell Carcinoma", "Recurrent Salivary Gland Carcinoma", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Major Salivary Gland Cancer AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Sinonasal Cancer AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Hypopharyngeal Carcinoma AJCC v8", "Stage IV Laryngeal Cancer AJCC v8", "Stage IV Lip and Oral Cavity Cancer AJCC v8", "Stage IV Major Salivary Gland Cancer AJCC v8", "Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IV Sinonasal Cancer AJCC v8", "Unresectable Head and Neck Cutaneous Squamous Cell Carcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hypopharyngeal Squamous Cell Carcinoma", "Unresectable Laryngeal Squamous Cell Carcinoma", "Unresectable Oral Cavity Squamous Cell Carcinoma", "Unresectable Oropharyngeal Squamous Cell Carcinoma", "Unresectable Paranasal Sinus Squamous Cell Carcinoma", "Unresectable Salivary Gland Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "OTHER", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-07-06", "completion_date": "2027-01-14", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 11, "location_summary": "Los Angeles, California • Chicago, Illinois • Ann Arbor, Michigan + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04576091" }, { "nct_id": "NCT04535401", "title": "Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Colorectal Carcinoma", "Advanced Digestive System Carcinoma", "Advanced Gastric Carcinoma", "Advanced Gastroesophageal Junction Adenocarcinoma", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Metastatic Colorectal Carcinoma", "Metastatic Digestive System Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Stage III Colorectal Cancer AJCC v8", "Stage IV Colorectal Cancer AJCC v8" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging Testing", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Leucovorin Calcium", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2021-08-13", "completion_date": "2027-07-01", "has_results": true, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 10, "location_summary": "Duarte, California • Bethesda, Maryland • City of Saint Peters, Missouri + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "City of Saint Peters", "state": "Missouri" }, { "city": "Creve Coeur", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT04535401" }, { "nct_id": "NCT04514497", "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Neuroendocrine Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Lung Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Neuroendocrine Carcinoma", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-10-20", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514497" }, { "nct_id": "NCT04491942", "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Bile Duct Carcinoma", "Advanced Breast Carcinoma", "Advanced Cervical Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Esophageal Carcinoma", "Advanced Gastric Carcinoma", "Advanced Head and Neck Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Lung Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Ovarian Carcinoma", "Advanced Penile Carcinoma", "Advanced Pleural Malignant Mesothelioma", "Advanced Urothelial Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Distal Bile Duct Cancer AJCC v8", "Stage III Intrahepatic Bile Duct Cancer AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Penile Cancer AJCC v8", "Stage III Pleural Diffuse Malignant Mesothelioma AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Distal Bile Duct Cancer AJCC v8", "Stage IV Intrahepatic Bile Duct Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Pleural Diffuse Malignant Mesothelioma AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2021-08-25", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 7, "location_summary": "Sacramento, California • Bethesda, Maryland • New York, New York + 3 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04491942" }, { "nct_id": "NCT05071209", "title": "Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Alveolar Rhabdomyosarcoma", "Recurrent Ewing Sarcoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Refractory Alveolar Rhabdomyosarcoma", "Refractory Ewing Sarcoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm" ], "interventions": [ { "name": "Elimusertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "12 Months to 30 Years" }, "enrollment_count": 31, "start_date": "2021-12-22", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05071209" }, { "nct_id": "NCT04616534", "title": "Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Fallopian Tube Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Ovarian Carcinoma", "Advanced Pancreatic Adenocarcinoma", "Advanced Primary Peritoneal Carcinoma", "Fallopian Tube High Grade Serous Adenocarcinoma", "Metastatic Pancreatic Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Primary Peritoneal High Grade Serous Adenocarcinoma", "Stage II Pancreatic Cancer AJCC v8", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging Testing", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2021-06-01", "completion_date": "2027-05-20", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 3, "location_summary": "Bethesda, Maryland • Boston, Massachusetts", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04616534" }, { "nct_id": "NCT04267939", "title": "ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors (Excluding Prostate Cancer)", "Ovarian Cancer" ], "interventions": [ { "name": "Elimusertib (BAY1895344)", "type": "DRUG" }, { "name": "Niraparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-02-26", "completion_date": "2023-12-01", "has_results": false, "last_update_posted_date": "2023-12-21", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 3, "location_summary": "Boston, Massachusetts • New York, New York • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04267939" }, { "nct_id": "NCT04095273", "title": "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "Elimusertib (BAY1895344)", "type": "DRUG" }, { "name": "Pembrolizumab (Keytruda®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2019-09-30", "completion_date": "2023-04-11", "has_results": false, "last_update_posted_date": "2024-04-02", "last_synced_at": "2026-09-02T21:49:56.905Z", "location_count": 8, "location_summary": "Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04095273" } ] }